Breaking News, Collaborations & Alliances

Takeda Licenses Late-Stage Cancer Drugs from Innovent in $1.2 Billion Deal

Takeda to bring Innovent’s next-gen IO Backbone therapy and ADC molecules to the global market.

Author Image

By: Charlie Sternberg

Associate Editor

Takeda Pharmaceutical Co. has signed a licensing and collaboration agreement with Innovent Biologics Inc. to develop and commercialize two late-stage oncology candidates outside of Greater China, the companies announced Tuesday. The deal includes IBI363, a bispecific antibody fusion protein targeting PD-1 and IL-2α, and IBI343, an antibody-drug conjugate (ADC) aimed at Claudin 18.2, a protein commonly expressed in gastric and pancreatic cancers. Takeda will also hold an exclusive option to li...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters